The Role of Antiepileptic Drugs

  • Mahinda Yogarajah
  • Marco MulaEmail author
Part of the Neuropsychiatric Symptoms of Neurological Disease book series (NSND)


Antiepileptic drugs (AEDs) suppress seizures by acting on a variety of mechanisms and molecular targets involved in the regulation of neuronal excitability. These include inhibitory (GABAergic) and excitatory (glutamatergic) neurotransmission, as well as ion (sodium and calcium) conductance through voltage-gated channels. However, these mechanisms and targets are also implicated in the regulation of mood and behavior, which may explain why each AED is associated with specific psychotropic effects. This chapter will discuss the role of mechanisms and molecular targets of AEDs in mood and behavior, and review the positive and negative psychotropic effects of AEDs.


Epilepsy Antiepileptic drugs Depression Psychosis Anxiety Anticonvulsant Mania Behavior 



Antiepileptic drug




European Medicines Agency






Food and Drug Administration






Hamilton Rating Scale for Anxiety






























  1. 1.
    Mula M. New antiepileptic drugs: molecular targets. Cent Nerv Syst Agents Med Chem. 2009;9(2):79–86.PubMedCrossRefGoogle Scholar
  2. 2.
    Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72(14):1223–9.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology. 2006;67(11):1916–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol. 2007;27(3):263–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord Int Epilepsy J Videotape. 2004;6(2):57–75.Google Scholar
  7. 7.
    Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30(7):555–67.PubMedCrossRefGoogle Scholar
  8. 8.
    White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85–110.PubMedCrossRefGoogle Scholar
  9. 9.
    Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999;53(5 Suppl 2):S53–67.PubMedGoogle Scholar
  10. 10.
    Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets. 2007;6(2):127–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Comai S, Tau M, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J Clin Psychopharmacol. 2012;32(1):83–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev. 2007;17(4):413–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Hauser P, Devinsky O, De Bellis M, Theodore WH, Post RM. Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders. Arch Neurol. 1989;46(6):696–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol Med. 1984;14(4):937–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Sheline YI. Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol Psychiatry. 1996;1(4):298–9.PubMedGoogle Scholar
  16. 16.
    Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57(10):925–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005;9(1):153–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Bagley J, Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience. 1997;77(1):65–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995;675(1–2):157–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Bartanusz V, Aubry JM, Pagliusi S, Jezova D, Baffi J, Kiss JZ. Stress-induced changes in messenger RNA levels of N-methyl-D-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus. Neuroscience. 1995;66(2):247–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993;150(11):1731–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology. 1998;37(3):124–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2002;5(3):255–75.Google Scholar
  24. 24.
    Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry. 2000;48(6):486–504.PubMedCrossRefGoogle Scholar
  25. 25.
    Naylor GJ, McNamee HB, Moody JP. Changes in erythrocyte sodium and potassium on recovery from a depressive illness. Br J Psychiatry. 1971;118(543):219–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Mendels J, Frazer A. Alterations in cell membrane activity in depression. Am J Psychiatry. 1974;131(11):1240–6.PubMedGoogle Scholar
  27. 27.
    El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv Rev Psychiatry. 2001;9(1):23–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Farber NB, Jiang X-P, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7(7):726–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Bhat S, Dao DT, Terrillion CE, Arad M, Smith RJ, Soldatov NM, et al. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol. 2012;99(1):1–14.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Mogilnicka E, Czyrak A, Maj J. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action. Eur J Pharmacol. 1987;138(3):413–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Galeotti N, Bartolini A, Ghelardini C. Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test. Neuropharmacology. 2006;50(3):309–16.PubMedCrossRefGoogle Scholar
  32. 32.
    Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renström E, Wietzorrek G, Berjukov S, et al. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca2+ channels. J Clin Invest. 2004;113(10):1430–9.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280(2):107–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ α2δ-1 subunit. J Pharmacol Exp Ther. 2011;338(1):240–5.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012;379(9820):1045–55.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Schloss P, Williams DC. The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol Oxf Engl. 1998;12(2):115–21.CrossRefGoogle Scholar
  37. 37.
    Whitton PS, Oresković D, Jernej B, Bulat M. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. J Pharm Pharmacol. 1985;37(3):199–200.PubMedCrossRefGoogle Scholar
  38. 38.
    Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+. Eur J Pharmacol. 1997;328(2–3):153–62.PubMedCrossRefGoogle Scholar
  39. 39.
    Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett. 2005;390(1):48–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Yamamura S, Hamaguchi T, Ohoyama K, Sugiura Y, Suzuki D, Kanehara S, et al. Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res. 2009;84(2–3):172–86.PubMedCrossRefGoogle Scholar
  41. 41.
    Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34(2–3):187–97.PubMedCrossRefGoogle Scholar
  42. 42.
    Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998;358(1):19–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry. 1992;33(2):115–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect. 1993;91(2–3):75–109.PubMedCrossRefGoogle Scholar
  45. 45.
    Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67 Suppl 6:3–8.PubMedGoogle Scholar
  46. 46.
    Löscher W, Hönack D. Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol. 1996;299(1–3):61–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22(3):193–205.PubMedCrossRefGoogle Scholar
  48. 48.
    Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10(7):685–92.PubMedCrossRefGoogle Scholar
  49. 49.
    Grunze HCR. Anticonvulsants in bipolar disorder. J Ment Health Abingdon Engl. 2010;19(2):127–41.CrossRefGoogle Scholar
  50. 50.
    Landolt H. Serial EEG investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorenz de Haas AM, editor. Lectures on Epilepsia. Amsterdam: Elsevier; 1958. p. 91–133.Google Scholar
  51. 51.
    Trimble MR, Schimtz B. Forced normalization and alternative psychoses of epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd.; 1998.Google Scholar
  52. 52.
    Gibbs FA. Ictal and non-ictal psychiatric disorders in temporal lobe epilepsy. J Nerv Ment Dis. 1951;113(6):522–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Tellenbach H. Epilepsy as a convulsive disorder and as a psychosis. on alternative psychoses of paranoid nature in ‘forced normlization’ (Landolt) of the electroencephalogram of epileptics. Nervenarzt. 1965;36:190–202.PubMedGoogle Scholar
  54. 54.
    Krishnamoorthy ES, Trimble MR, Sander JWAS, Kanner AM. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav. 2002;3(4):303–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Seethalakshmi R, Krishnamoorthy ES. The complex relationship between seizures and behavior: an illustrative case report. Epilepsy Behav. 2007;10(1):203–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Gatzonis SD, Stamboulis E, Siafakas A, Angelopoulos E, Georgaculias N, Sigounas E, et al. Acute psychosis and EEG normalisation after vagus nerve stimulation. J Neurol Neurosurg Psychiatry. 2000;69(2):278–9.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Krishnamoorthy ES, Trimble MR. Forced normalization: clinical and therapeutic relevance. Epilepsia. 1999;40 Suppl 10:S57–64.PubMedCrossRefGoogle Scholar
  58. 58.
    Wolf P. Acute behavioural symptomatology at disappearance of epileptiform EEG abnormality: paradoxical or forced normalization. In: Smith D, Treiman D, Trimble MR, editors. Neurobehavioural problems in epilepsy. New York: Raven Press; 1991.Google Scholar
  59. 59.
    Wolf P, Trimble MR. Biological antagonism and epileptic psychosis. Br J Psychiatry J Ment Sci. 1985;146:272–6.CrossRefGoogle Scholar
  60. 60.
    Seethalakshmi R, Krishnamoorthy ES. Depression in epilepsy: phenomenology, diagnosis and management. Epileptic Disord Int Epilepsy J Videotape. 2007;9(1):1–10.Google Scholar
  61. 61.
    Gilliam F. The impact of epilepsy on subjective health status. Curr Neurol Neurosci Rep. 2003;3(4):357–62.PubMedCrossRefGoogle Scholar
  62. 62.
    Harden CL, Maroof DA, Nikolov B, Fowler K, Sperling M, Liporace J, et al. The effect of seizure severity on quality of life in epilepsy. Epilepsy Behav. 2007;11(2):208–11.PubMedCrossRefGoogle Scholar
  63. 63.
    Turky A, Beavis JM, Thapar AK, Kerr MP. Psychopathology in children and adolescents with epilepsy: an investigation of predictive variables. Epilepsy Behav. 2008;12(1):136–44.PubMedCrossRefGoogle Scholar
  64. 64.
    Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia. 1999;40 Suppl 10:S21–47.PubMedCrossRefGoogle Scholar
  65. 65.
    Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology. 1999;53(7):1503–11.PubMedCrossRefGoogle Scholar
  66. 66.
    Trimble MR, Rüsch N, Betts T, Crawford PM. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure. 2000;9(4):249–54.PubMedCrossRefGoogle Scholar
  67. 67.
    Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003;44(5):659–63.PubMedCrossRefGoogle Scholar
  68. 68.
    White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010;75(6):513–8.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Trimble MR. Biological psychiatry. 2nd ed. Chichester: Wiley; 1996.Google Scholar
  70. 70.
    Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord. 1995;34(4):275–81.PubMedCrossRefGoogle Scholar
  71. 71.
    Rodin EA, Katz M, Lennox K. Differences between patients with temporal lobe seizures and those with other forms of epileptic attacks. Epilepsia. 1976;17(3):313–20.PubMedCrossRefGoogle Scholar
  72. 72.
    Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80(6):909–17.PubMedGoogle Scholar
  73. 73.
    Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, Sosa AL, Espinola M, Ruiz I. Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav. 2005;6(3):413–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Vining EP, Mellitis ED, Dorsen MM, Cataldo MF, Quaskey SA, Spielberg SP, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80(2):165–74.PubMedGoogle Scholar
  75. 75.
    Ring HA, Crellin R, Kirker S, Reynolds EH. Vigabatrin and depression. J Neurol Neurosurg Psychiatry. 1993;56(8):925–8.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res. 1996;25(1):21–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet. 1999;354(9172):13–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand. 1996;93(1):1–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52(2):321–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology. 2002;58(3):368–72.PubMedCrossRefGoogle Scholar
  81. 81.
    Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia. 2009;50(5):1072–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Nickel C, Lahmann C, Tritt K, Muehlbacher M, Kaplan P, Kettler C, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord. 2005;87(2–3):243–52.PubMedCrossRefGoogle Scholar
  83. 83.
    Mowla A, Kardeh E. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):970–3.PubMedCrossRefGoogle Scholar
  84. 84.
    Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57(5):495–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1515–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvärinen S, Eronen M, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005;66(8):1012–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol Oxf Engl. 2009;23(2):157–62.CrossRefGoogle Scholar
  88. 88.
    Muscatello MRA, Bruno A, Pandolfo G, Micò U, Bellinghieri PM, Scimeca G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol Oxf Engl. 2011;25(5):667–74.CrossRefGoogle Scholar
  89. 89.
    Leombruni P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr Dis Treat. 2009;5:385–92.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat. 2006;2(4):475–88.PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia. 1998;39(1):33–42.PubMedCrossRefGoogle Scholar
  92. 92.
    Suppes T, Chisholm KA, Dhavale D, Frye MA, Altshuler LL, McElroy SL, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. 2002;4(5):283–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003;64(10):1245–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Leppik IE. Tiagabine: the safety landscape. Epilepsia. 1995;36 Suppl 6:S10–3.PubMedCrossRefGoogle Scholar
  95. 95.
    Wroe SJ. Zonisamide. In: Shorvon S, Perucca E, Engel Jr J, editors. The treatment of epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009. p. 713–20.CrossRefGoogle Scholar
  96. 96.
    Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H. [3H]zonisamide binding in rat brain. Med J Osaka Univ. 1990;39(1–4):19–22.PubMedGoogle Scholar
  97. 97.
    Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003;116(1–2):1–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol. 1998;124(6):1277–85.PubMedCentralPubMedCrossRefGoogle Scholar
  99. 99.
    Mula M, Trimble MR, Sander JWAS. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia. 2003;44(12):1573–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Quiske A, Helmstaedter C, Lux S, Elger CE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res. 2000;39(2):121–5.PubMedCrossRefGoogle Scholar
  101. 101.
    Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157(1):115–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Frodl T, Meisenzahl EM, Zetzsche T, Born C, Groll C, Jäger M, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry. 2002;159(7):1112–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms. A preliminary report. Br J Psychiatry J Ment Sci. 1974;124:440–5.CrossRefGoogle Scholar
  104. 104.
    Sander JW, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res. 1992;13(1):89–92.PubMedCrossRefGoogle Scholar
  105. 105.
    Reynolds EH. Mental effects of antiepileptic medication: a review. Epilepsia. 1983;24 Suppl 2:S85–95.PubMedCrossRefGoogle Scholar
  106. 106.
    Fischer M, Korskjaer G, Pedersen E. Psychotic episodes in Zarondan treatment. Effects and side-effects in 105 patients. Epilepsia. 1965;6(4):325–34.PubMedCrossRefGoogle Scholar
  107. 107.
    Roger J, Grangeon H, Gueyj J, Lob H. Psychiatric and psychologic effects of ethosuximide treatment of epileptics. Encéphale. 1968;57(5):407–38.PubMedGoogle Scholar
  108. 108.
    Pakalnis A, Drake ME, John K, Kellum JB. Forced normalization. Acute psychosis after seizure control in seven patients. Arch Neurol. 1987;44(3):289–92.PubMedCrossRefGoogle Scholar
  109. 109.
    McConnell H, Snyder PJ, Duffy JD, Weilburg J, Valeriano J, Brillman J, et al. Neuropsychiatric side effects related to treatment with felbamate. J Neuropsychiatry Clin Neurosci. 1996;8(3):341–6.PubMedCrossRefGoogle Scholar
  110. 110.
    Mula M, Trimble MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav. 2003;4(4):430–4.PubMedCrossRefGoogle Scholar
  111. 111.
    Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry. 1991;54(5):435–9.PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Kimura S. Zonisamide-induced behavior disorder in two children. Epilepsia. 1994;35(2):403–5.PubMedCrossRefGoogle Scholar
  113. 113.
    Tsuji M, Hori S, Asai N, Hamanaka T, Ishikawa T, Hiyoshi T, et al. Two epileptics showing antiepileptic drug-induced psychoses. Jpn J Psychiatry Neurol. 1993;47(2):298–9.PubMedGoogle Scholar
  114. 114.
    Brandt C, Fueratsch N, Boehme V, Kramme C, Pieridou M, Villagran A, et al. Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. Epilepsy Behav. 2007;11(1):133–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Sackellares JC, Krauss G, Sommerville KW, Deaton R. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia. 2002;43(4):394–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure. 1996;5(2):153–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Trimble MR. New antiepileptic drugs and psychopathology. Neuropsychobiology. 1998;38(3):149–51.PubMedCrossRefGoogle Scholar
  118. 118.
    Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia. 1999;40 Suppl 10:S65–70.PubMedCrossRefGoogle Scholar
  119. 119.
    Pal DK. Phenobarbital for childhood epilepsy: systematic review. Paediatr Perinat Drug Ther. 2006;7(1):31–42.PubMedCentralPubMedCrossRefGoogle Scholar
  120. 120.
    Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet. 1998;351(9095):19–23.PubMedCrossRefGoogle Scholar
  121. 121.
    Bhaumik S, Branford D, Duggirala C, Ismail IA. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure. 1997;6(2):127–33.PubMedCrossRefGoogle Scholar
  122. 122.
    White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak TE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003;61(9):1218–21.PubMedCrossRefGoogle Scholar
  123. 123.
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861–6.PubMedCentralPubMedCrossRefGoogle Scholar
  124. 124.
    Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs. 2006;20(12):969–79.PubMedCrossRefGoogle Scholar
  125. 125.
    Zhang W, Connor KM, Davidson JRT. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol Oxf Engl. 2005;19(5):551–3.CrossRefGoogle Scholar
  126. 126.
    Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(6):744–50.PubMedCrossRefGoogle Scholar
  127. 127.
    Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010;71(5):627–31.PubMedCrossRefGoogle Scholar
  128. 128.
    Mattes JA. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(2):310–5.PubMedCrossRefGoogle Scholar
  129. 129.
    Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61(5):704–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Helmstaedter C, Mihov Y, Toliat MR, Thiele H, Nuernberg P, Schoch S, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013;54(1):36–44.PubMedCrossRefGoogle Scholar
  131. 131.
    Lhatoo SD, Sander JW. The epidemiology of epilepsy and learning disability. Epilepsia. 2001;42 Suppl 1:6–9; discussion 19–20.PubMedCrossRefGoogle Scholar
  132. 132.
    Besag FMC. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf. 2004;3(1):1–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010;9(4):413–24.PubMedCrossRefGoogle Scholar
  134. 134.
    Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA, et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(6):539–47.PubMedCrossRefGoogle Scholar
  135. 135.
    Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR, Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(11):1698–706.PubMedCrossRefGoogle Scholar
  136. 136.
    Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27(6):677–81.PubMedCrossRefGoogle Scholar
  137. 137.
    Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu S-C, Capece JA, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(2):201–6.PubMedCrossRefGoogle Scholar
  138. 138.
    Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006;163(7):1179–86.PubMedCrossRefGoogle Scholar
  139. 139.
    Vasudev A, Macritchie K, Watson S, Geddes JR, Young AH. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2008;(1):CD005171.Google Scholar
  140. 140.
    Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2011;(12):CD004857.Google Scholar
  141. 141.
    Bourgeois BFD. Valproate. In: Shorvon S, Perucca E, Engel Jr J, editors. The treatment of epilepsy. 3rd ed. Chichester: Wiley-Blackwell; 2009. p. 685–98.CrossRefGoogle Scholar
  142. 142.
    Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett. 1990;116(1–2):233–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Machado-Vieira R, Ibrahim L, Zarate CA. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther. 2011;17(6):699–704.PubMedCentralPubMedCrossRefGoogle Scholar
  144. 144.
    Macritchie K, Geddes J, Scott J, Haslam DR, Silva de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. In: The Cochrane Collaboration, editor. Cochrane Database Syst Rev [Internet]. Chichester: Wiley; 2003 [Cited 28 Jan 2015]. Available from:
  145. 145.
    Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010;122(1–2):1–9.PubMedCrossRefGoogle Scholar
  146. 146.
    Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67(10):1501–10.PubMedCrossRefGoogle Scholar
  147. 147.
    Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2003;28(7):1374–82.CrossRefGoogle Scholar
  148. 148.
    Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010;124(3):228–34.PubMedCrossRefGoogle Scholar
  149. 149.
    Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry. 2000;61(2):123–8.PubMedCrossRefGoogle Scholar
  150. 150.
    Post RM, Ketter TA, Uhde T, Ballenger JC. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007;21(1):47–71.PubMedCrossRefGoogle Scholar
  151. 151.
    Weisler RH, Kalali AH, Ketter TA, SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004;65(4):478–84.PubMedCrossRefGoogle Scholar
  152. 152.
    Weisler RH, Keck PE, Swann AC, Cutler AJ, Ketter TA, Kalali AH, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66(3):323–30.PubMedCrossRefGoogle Scholar
  153. 153.
    Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – a randomised study. J Affect Disord. 1997;43(2):151–61.PubMedCrossRefGoogle Scholar
  154. 154.
    Hartong EGTM, Moleman P, Hoogduin CAL, Broekman TG, Nolen WA, LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry. 2003;64(2):144–51.PubMedCrossRefGoogle Scholar
  155. 155.
    Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998;18(6):455–60.PubMedCrossRefGoogle Scholar
  156. 156.
    Zhang Z-J, Tan Q-R, Tong Y, Li Q, Kang W-H, Zhen X-C, et al. The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study. J Affect Disord. 2008;109(1–2):91–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2007;(3):CD001258.Google Scholar
  158. 158.
    Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology. 2000;39(11):2139–46.PubMedCrossRefGoogle Scholar
  159. 159.
    Meldrum BS. Lamotrigine – a novel approach. Seizure. 1994;3(Suppl A):41–5.PubMedGoogle Scholar
  160. 160.
    Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport. 2001;12(10):2255–8.PubMedCrossRefGoogle Scholar
  161. 161.
    Zona C, Tancredi V, Longone P, D’Arcangelo G, D’Antuono M, Manfredi M, et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia. 2002;43(7):685–90.PubMedCrossRefGoogle Scholar
  162. 162.
    Kocki T, Wielosz M, Turski WA, Urbanska EM. Enhancement of brain kynurenic acid production by anticonvulsants--novel mechanism of antiepileptic activity? Eur J Pharmacol. 2006;541(3):147–51.PubMedCrossRefGoogle Scholar
  163. 163.
    Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013;74(7):675–84.PubMedCrossRefGoogle Scholar
  164. 164.
    Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65(3):432–41.PubMedCrossRefGoogle Scholar
  165. 165.
    Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9.PubMedCrossRefGoogle Scholar
  166. 166.
    Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol. 2007;22(3):179–82.PubMedCrossRefGoogle Scholar
  167. 167.
    Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007;10(1):148–54.PubMedCrossRefGoogle Scholar
  168. 168.
    Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007;27(6):582–9.PubMedCrossRefGoogle Scholar
  169. 169.
    Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004;56(6):441–6.PubMedCrossRefGoogle Scholar
  170. 170.
    Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24(5):270–5.PubMedGoogle Scholar
  171. 171.
    Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol Oxf Engl. 2005;19(3):287–91.CrossRefGoogle Scholar
  172. 172.
    Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia. 1998;39(3):280–2.PubMedCrossRefGoogle Scholar
  173. 173.
    Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry. 2000;157(3):463–5.PubMedCrossRefGoogle Scholar
  174. 174.
    Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord. 2003;5(6):464–7.PubMedCrossRefGoogle Scholar
  175. 175.
    Nemets B, Bersudsky Y, Belmaker RH. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J Clin Psychiatry. 2005;66(5):586–90.PubMedCrossRefGoogle Scholar
  176. 176.
    Stanford MS, Helfritz LE, Conklin SM, Villemarette-Pittman NR, Greve KW, Adams D, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol. 2005;13(1):72–7.PubMedCrossRefGoogle Scholar
  177. 177.
    Andrews G. The treatment of anxiety disorders: clinician guides and patient manuals. 2nd ed. Cambridge: Cambridge University Press; 2003.Google Scholar
  178. 178.
    Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23(2):121–37.PubMedCrossRefGoogle Scholar
  179. 179.
    Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341–8.PubMedCrossRefGoogle Scholar
  180. 180.
    Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000;2(3 Pt 2):249–55.PubMedCrossRefGoogle Scholar
  181. 181.
    Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607–14.PubMedCrossRefGoogle Scholar
  182. 182.
    Vieta E, Manuel Goikolea J, Martínez-Arán A, Comes M, Verger K, Masramon X, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry. 2006;67(3):473–7.PubMedCrossRefGoogle Scholar
  183. 183.
    Wolf SM, Shinnar S, Kang H, Gil KB, Moshé SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia. 1995;36(12):1203–5.PubMedCrossRefGoogle Scholar
  184. 184.
    Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. Epilepsia. 1996;37(1):87–90.PubMedCrossRefGoogle Scholar
  185. 185.
    Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389–94.PubMedCrossRefGoogle Scholar
  186. 186.
    Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009;24(2):87–96.PubMedCrossRefGoogle Scholar
  187. 187.
    Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011;26(4):213–20.PubMedCrossRefGoogle Scholar
  188. 188.
    Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011;26(5):243–51.PubMedCrossRefGoogle Scholar
  189. 189.
    Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022–30.PubMedCrossRefGoogle Scholar
  190. 190.
    Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771–82.PubMedCrossRefGoogle Scholar
  191. 191.
    Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2008;18(6):422–30.CrossRefGoogle Scholar
  192. 192.
    Montgomery SA, Herman BK, Schweizer E, Mandel FS. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol. 2009;24(4):214–22.PubMedCrossRefGoogle Scholar
  193. 193.
    Feltner D, Wittchen H-U, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18–28.PubMedCrossRefGoogle Scholar
  194. 194.
    Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol. 2010;30(4):437–40.PubMedCrossRefGoogle Scholar
  195. 195.
    Showraki M. Pregabalin in the treatment of depression. J Psychopharmacol Oxf Engl. 2007;21(8):883–4.CrossRefGoogle Scholar
  196. 196.
    Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826–36.PubMedCrossRefGoogle Scholar
  197. 197.
    Yuen AWC, Singh R, Bell GS, Bhattacharjee A, Neligan A, Heaney DC, et al. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res. 2009;87(2–3):120–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Epilepsy GroupAtkinson Morley Regional Neuroscience Centre, St. George’s University Hospitals NHS Foundation TrustLondonUK
  2. 2.Institute of Medical and Biomedical SciencesSt George’s University of LondonLondonUK

Personalised recommendations